KOBV Portal

Hits per page

hit 1 - 1 | 1 hit

Select All Export

Online Resource

Table_4.xlsx

Iwasaki, Makoto ; Kanda, Junya ; Tanaka, Hidenori ; [et al.]

Frontiers Media SA ; 2022

In: Frontiers in Immunology Vol. 13 ( 2022-3-3)

add to watchlist on the watchlist

Details

In: Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-3-3)

Abstract: The significance of antibody-identified epitopes stimulating humoral alloimmunity is not well understood in the identification of non-permissive human leukocyte antigen (HLA) mismatching patterns in hematopoietic stem cell transplantation (HSCT). This was a retrospective study in a cohort of 9,991 patients who underwent their first HSCT for hematologic malignancies from unrelated bone marrow donors in the Transplant Registry Unified Management Program (TRUMP). HLA eplet mismatches (EMM) were quantified using HLAMatchmaker (HLAMM). The median age of patients was 48 years (range, 16 to 77). The number of EMM in recipient-donor pairs in our study population ranged from 0 to 37 in HLA class I (median, 0) and 0 to 60 in HLA class II (median, 1). In addition to the known high-risk mismatch patterns in the Japanese cohort, HLA-C EMM in the GVH direction was associated with a significantly higher risk for grade III-IV aGVHD, leading to a higher risk of non-relapse mortality and lower overall survival (compared with HLA-C matched patients, HR 1.67, 95% CI 1.44–1.95; HR 1.39, 95% CI 1.25–1.54; HR 1.20, 95% CI 1.10–1.30, respectively). HLAMM-based epitope matching might be useful for identifying patients who are at high risk for serious complications after HSCT from HLA mismatched unrelated donors.

Type of Medium: Online Resource

ISSN: 1664-3224

URL: Article